MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » St. Jude Medical beats The Street, lowers guidance

St. Jude Medical beats The Street, lowers guidance

By

St. Jude Medical

St. Jude Medical (NYSE:STJ) beat Wall Street’s forecasts for its third-quarter sales and earnings, sending its shares up nearly 5 percent in early-morning trading despite a lower forecast for full-year earnings.

Profits were up 8.7 percent and sales rose 11.5 percent for the St. Paul, Minn.-based medical device maker, which posted earnings of $226.5 million, or 69 cents per diluted share, on sales of $1.38 billion during the three months ended Oct. 1. That compares with profits of $208.4 million, or 63 cents diluted EPS, on sales of $1.24 billion during the same period last year.

St. Jude’s adjusted EPS was 78 cents per share, excluding charges of $20.9 million (6 cents per share) "primarily related to ongoing restructuring actions that began in the second quarter to realign certain activities in our CRM business as well as employee termination and other costs primarily associated with continuing efforts to improve our international sales & sales support organization," according to a press release, and another $8.5 million (3 cents per share) "related to increased collection risk for accounts receivable related to one customer in Europe." Analysts had expected adjusted EPS of 76 cents per share and St. Jude’s own forecast was for 74 cents to 76 cents.

Sign up to get our free newsletters delivered right to your inbox

But the company cut its prediction for full-year adjusted earnings from $3.25 to $3.30 down to between $3.26 and $3.28 per share; The Street has its hopes pegged on adjusted EPS of $3.27 per share.

Sales of implantable cardiac defibrillators and pacemakers were up 2 percent to $751 million, with ICD sales up 1 percent to $445 million and pacemaker sales up 2 percent to $306 million. Atrial fibrillation sales rose 20 percent to $202 million; neuromodulation sales rose 10 percent to $102 million. Vascular and structural heart product sales were $328 million, up 37 percent including revenues from AGA Medical Inc., which St. Jude bought last year for $1.03 billion.

Sales of vascular products in the third quarter of 2011 were $177 million, up 10 percent from the comparable quarter in 2010.

Structural heart product sales for the third quarter of 2011 were $151 million, a 91 percent increase over the third quarter of 2010, with the addition of AGA Medical products to the business.

STJ shares were up nearly 4.5 percent to $39 as of about 10:15 this morning.

In case you missed it

RSS From Medical Design & Outsourcing

  • Forecasting the future of urology with Boston Scientific’s Meghan Scanlon
    Meghan Scanlon, Boston Scientific’s president of urology and pelvic health, discusses the field and the challenges and opportunities ahead. The urology specialty faces a critical moment, with 10 urologists ready to retire for every new urologist entering the field, said Meghan Scanlon, SVP and president of urology and pelvic health at Boston Scientific (NYSE:BSX) That… […]
  • Women researchers receive a fraction of funding from the world’s biggest medtech companies
    The gender divide in medtech extends beyond leadership and into funding for investigational studies by U.S. physicians. Only 6.7% of physicians who received research payments from the world’s largest medical device companies in 2020 were women, according to an analysis of Medical Design & Outsourcing’s Big 100 list of medtech companies and CMS Open Payments… […]
  • Pentax Medical expands Vizient contract to include pediatric endoscopes
    Pentax Medical today announced it has expanded its contract with Vizient to include pediatric endoscopes. The contract will give Pentax Medical the ability to offer endoscopes to Vizient member hospitals through the Vizient Pediatric Program. The agreement also includes other value-added offerings, education opportunities and best practices. Get the full story on our sister site,… […]
  • Hologic plans to buy Bolder Surgical for $160M
    Hologic Inc. (NSDQ:HOLX) has a $160 million deal to acquire Bolder Surgical, a developer and manufacturer of advanced energy vessel sealing surgical devices. It’s the latest deal by Hologic, which has been spending COVID-19 test revenue generated by its diagnostics business on acquisitions across the company’s business lines, as CFO Karleen Oberton and CEO Steve MacMillan… […]
  • Koya Medical reports positive early results in Dayspring lymphedema trial
    Koya Medical this week announced positive results from a small, ongoing trial comparing its Dayspring compression treatment for lymphedema to a traditional pneumatic compression pump. The Oakland, California-based company secured FDA 510(k) clearance for the device last month, saying it was the first such approval for an active compression treatment enabling movement and mobility with… […]
  • OneProjects raises $17M to advance 4D cardiac imaging
    Irish-German cardiac imaging startup OneProjects today announced $8 million in Series A2 funding and two grants totaling $9 million. The company will use the new funds to complete product development, conduct clinical trials, gain FDA clearance and prepare for U.S. commercialization of the first product developed from its proprietary 4D cardiac imaging platform, Verafeye. The… […]
  • Women in Medtech 2021: Lindsay Fleming, Avient Corp. Commercial Manager, Healthcare — Color & Additives
    Lindsay Fleming is the Healthcare Commercial Manager for the Color & Additives division at Avient Corporation, a premier provider of specialty polymer formulations, color and additive systems, packaging solutions, and polymer distribution. She has been with the company for over 7 years and oversees the commercial growth development of the healthcare segment. She focuses on… […]
  • Women in Medtech 2021: Sarah Ehrlich, Argon Medical Devices Sustaining Mechanical Engineer
    Sarah Ehrlich, sustaining mechanical engineer at Argon Medical Devices, holds a B.S in mechanical engineering from the University of Texas at Tyler. “My parents knew I would become an engineer before I did,” she said. “Growing up, I was the big sister who put back together whatever my younger siblings decided to tear apart. I… […]
  • Four questions with AdvaMed’s Jen Brearey
    Jen Brearey is AdvaMed’s chief financial officer and chief operating officer, as well as executive director for the association’s inclusion diversity programs, which includes the industry initiative AdvaMed Advance and AdvaMed’s Women’s Executive Network. Ahead of our annual Women in Medtech edition of Medical Design & Outsourcing, we asked Brearey to share her expertise on gender… […]
  • Life Spine wins FDA clearance for ProLift micro expandable spacer
    Life Spine announced that it received FDA clearance to market its ProLift micro expandable spacer system for supporting micro-invasive procedures. Huntley, Illinois-based Life Spine designed its ProLift micro to support procedures ranging from endoscopic TLIFs to MIS TLIFs/PLIFs. The platform includes an 8mm width, self-locking expansion at any height (between 8mm and 16mm) to suit… […]
  • Achieve More with Medical Device Training and Certifications
    Any medical professional that deals with complex devices on a regular basis can benefit greatly from a wide range of medical device courses offered by The Center for Professional Innovation and Education (CfPIE). Each course offered is designed to advance your career under the instruction of trained, experienced, and actively practicing professionals in the field.… […]

Leave a Reply